Methamphetamine

Dose and frequency are the dominant variables. A single low-dose exposure typically clears the SAMHSA 500 ng/mL urinary cutoff within 24 to 72 hours. Chronic heavy users — those engaged in extended binge use over multiple days — can remain positive for a week or longer after the last exposure because the elimination kinetics of methamphetamine and its amphetamine metabolite create a long tail at the end of a binge episode. Methamphetamine does not accumulate in adipose tissue the way THC does, but the relatively long parent-drug half-life means each successive dose extends the detection window.

Route of administration affects pharmacokinetic peaks but has less effect on urinary detection windows than dose. Smoked and intravenous methamphetamine produce rapid onset and very high peak plasma concentrations within minutes. Insufflated methamphetamine reaches peak in roughly 15 minutes; oral ingestion in two to three hours. All routes converge on the same hepatic metabolic pathway, so total dose is a better predictor of urinary detection than route.

Hepatic metabolism via CYP2D6 is the primary clearance pathway. CYP2D6 is genetically polymorphic — roughly 5 to 10 percent of individuals are poor metabolizers and a smaller percentage are ultra-rapid metabolizers — which produces meaningful inter-individual variability in clearance. Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) extend methamphetamine clearance and the detection window; CYP2D6 inducers are uncommon. Hepatic impairment from cirrhosis, hepatitis, or other causes prolongs clearance modestly.

Urinary pH is a notable modifier for methamphetamine specifically. Methamphetamine is a weak base, and excretion is markedly pH-dependent: acidic urine substantially increases renal clearance of unchanged parent drug, while alkaline urine decreases it. This is a published pharmacology finding and is one reason urinary detection windows for methamphetamine are more variable than for some other analytes. Hydration status, body composition, age, and concurrent medications all play smaller modifying roles.

SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs set the initial immunoassay cutoff for amphetamines — which includes both amphetamine and methamphetamine — at 500 ng/mL in urine. Specimens that test at or above this level proceed to confirmation by GC/MS or LC-MS/MS, where the confirmatory cutoff is 250 ng/mL. For a specimen to be reported as methamphetamine-positive, SAMHSA requires that amphetamine also be present at a concentration of 100 ng/mL or higher; this requirement is intended to confirm that the methamphetamine is metabolizing as expected and to reduce the rate of certain artifactual or contamination-related positives.

MDMA (and its primary metabolite MDA) is reported separately under SAMHSA's 2017 guidelines update at 500 ng/mL screening and 250 ng/mL confirmation. Older non-SAMHSA immunoassays often grouped methamphetamine, amphetamine, and MDMA under a single "amphetamines" cutoff; modern panels typically distinguish them at the immunoassay level or at confirmation. Non-federal employers and clinical programs are free to set their own cutoffs; lower cutoffs (e.g., 300 ng/mL screening) are sometimes used in substance-use-disorder treatment programs for greater sensitivity to recent use.

Saliva and hair testing use different thresholds. SAMHSA's oral-fluid guidelines specify a 50 ng/mL initial cutoff for methamphetamine and a 50 ng/mL confirmation cutoff, with the same 100 ng/mL amphetamine-presence requirement adapted for oral fluid. Hair testing is not yet a SAMHSA-authorized matrix for federal programs as of this writing; commercial laboratories commonly use 500 pg/mg for methamphetamine on hair, with the explicit limitation that hair cannot localize use within the 90-day window.

Lateral-flow immunoassay is the standard format for point-of-care methamphetamine screening. The test strip contains a membrane impregnated with antibodies raised against methamphetamine and a colored conjugate. When urine wicks up the strip, free methamphetamine in the sample competes with the labeled conjugate for antibody binding sites; sufficient methamphetamine at or above the device cutoff produces a no-test-line positive result. The control line confirms reagent function. All Magenta dip cards and cups use this format and produce a read in approximately five minutes.

Cross-reactivity is a well-known issue for amphetamines immunoassays — historically more so than for any other class of drug-of-abuse test. The antibodies cannot distinguish d-methamphetamine (illicit and prescription Desoxyn) from l-methamphetamine (OTC Vicks Vapor Inhaler and metabolic product of selegiline). They also cross-react with MDMA and MDA, and to varying degrees with structurally related sympathomimetics including pseudoephedrine, phentermine, bupropion metabolites, and certain over-the-counter cold-and-allergy ingredients. Modern devices have improved specificity over older generations, but the package insert cross-reactivity table remains essential reading for any program that screens for amphetamines.

The l-meth versus d-meth distinction is the single most important confirmation issue. A positive immunoassay screen cannot determine whether the methamphetamine present is the illicit d-isomer or the OTC-inhaler-derived l-isomer. Chiral GC/MS or LC-MS/MS confirmation resolves this by separating and quantifying the two enantiomers. A specimen reported as predominantly l-methamphetamine with minimal d-methamphetamine is consistent with use of a Vicks Vapor Inhaler, levmetamfetamine nasal preparations, or metabolism of selegiline. A specimen reported as predominantly d-methamphetamine is consistent with illicit use or with prescription Desoxyn (which should be documented by the donor to the Medical Review Officer).

Confirmation testing by GC/MS or LC-MS/MS is the gold standard for resolving any presumptive positive. SAMHSA-certified laboratories perform confirmation on every screening positive in federally regulated programs, applying the 250 ng/mL methamphetamine and 100 ng/mL amphetamine quantitation requirements. A Medical Review Officer reviews confirmed positives against documented prescriptions (Desoxyn, selegiline, Adderall, Vyvanse) before any adverse action. Programs operating in jurisdictions with significant ADHD or narcolepsy prescription density should expect a meaningful number of MRO-cleared positives.

Specimen validity testing accompanies every methamphetamine screen. Laboratories and point-of-care devices check creatinine and specific gravity to identify dilute specimens, pH to identify adulteration, and oxidizing-agent panels to identify products marketed to defeat drug tests. Magenta's adulteration-panel cups include creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant pads. A positive adulteration finding generally triggers a refusal-to-test consequence under federal rules, equivalent to a confirmed positive.